Incidence and Outcomes of Aneurysmal Subarachnoid Hemorrhage: A Multicenter Retrospective Registry-based Descriptive Trial in Kobe City
-
- OHTA Tsuyoshi
- Department of Neurosurgery, Kobe City Medical Center General Hospital
-
- MATSUMOTO Shirabe
- Department of Neurosurgery, Kobe City Medical Center General Hospital
-
- FUKUMITSU Ryu
- Department of Neurosurgery, Kobe City Medical Center General Hospital
-
- IMAMURA Hirotoshi
- Department of Neurosurgery, Kobe City Medical Center General Hospital
-
- ADACHI Hidemitsu
- Department of Neurosurgery, Kobe City Medical Center West Hospital
-
- HARA Yoshie
- Department of Neurosurgery, Hyogo Emergency Medical Center and Kobe Red Cross Hospital
-
- HOSODA Kohkichi
- Department of Neurosurgery, Kobe City Nishi-Kobe Medical Center
-
- KIMURA Hidehito
- Department of Neurosurgery, Kobe University Graduate School of Medicine
-
- KUWAYAMA Kazuyuki
- Department of Neurosurgery, Japan Community Health Care Organization Kobe Central Hospital
-
- MIZOWAKI Takashi
- Department of Neurosurgery, Shinsuma General Hospital
-
- MOTOOKA Yasuhiko
- Department of Neurosurgery, Konan Medical Center
-
- MIYATA Shiro
- Department of Neurosurgery, Kobe Ekisaikai Hospital
-
- SHINODA Narihide
- Department of Neurosurgery, Kosei Hospital
-
- UENO Yasushi
- Department of Neurosurgery, Shinko Memorial Hospital
-
- YAMAURA Ikuya
- Department of Neurosurgery, Cerebrovascular Research Institute, Yoshida Hospital
-
- YOSHIDA Yasuhisa
- Department of Neurosurgery, Cerebrovascular Research Institute, Yoshida Hospital
-
- SAKAI Chiaki
- Department of Neurovascular Research, Kobe City Medical Center General Hospital
-
- SAKAI Nobuyuki
- Department of Neurovascular Research, Kobe City Medical Center General Hospital
抄録
<p>The current study aims to evaluate the incidence and results of aneurysmal subarachnoid hemorrhage (aSAH) throughout Kobe City. Based on a multicenter retrospective registry-based descriptive trial involving all 13 primary stroke centers in Kobe City, patients with aSAH treated between October 2017 and September 2019 were studied. A total of 334 patients were included, with an estimated age-adjusted incidence of 11.12 per 100,000 person-years. Curative treatment was given to 94% of patients, with endovascular treatment (51%) preferred over surgical treatment (43%). Of the patients, 12% were treated by shunt surgery for sequential hydrocephalus with a worse outcome at 30 days or discharge (14% vs. 46%, odds ratio (OR): 0.19, 95% confidence interval (CI): 0.088-0.39, p-value <0.001). As for vasospasm and delayed cerebral ischemia, most patients were given intravenous fasudil infusion (73%), with endovascular treatment for vasospasm in 24 cases (7.2%). The fasudil group had more good outcomes (42% vs. 30%, OR: 1.64, 95% CI: 0.95-2.87, p-value = 0.075) and significantly less death (3.3% vs. 35%, OR: 0.064, 95% CI: 0.024-0.15, p-value <0.001) at 30 days or discharge. Mortality rose from 12% at 30 days or discharge to 17% at 1 year, but neurological function distribution improved over time (modified Rankin Scale 0-2 was 39% at 30 days or discharge, 53% at 60 days, and 63% at 1 year). Our retrospective registered trial presented various statistics on aSAH, summarizing the current treatment status and prognosis.</p>
収録刊行物
-
- Neurologia medico-chirurgica
-
Neurologia medico-chirurgica 63 (11), 519-525, 2023-11-15
一般社団法人 日本脳神経外科学会